Statins: Cholesterol guidelines and Indian perspective

Indian Journal of Endocrinology and Metabolism

Volumn 19, Issue 5, 2015, Pages 546-553

  Menon, Anil S ^a   Kotwal, Narendra ^b   Singh, Yashpal ^c   Girish, R ^a  

^a Department of Laboratory Medicine and Transfusion Medicine   (India)

^b ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^c ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

Asian Indians; lipids; statins

Indexed keywords

EID: 84981180121     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.163105     Document Type: Review

References (50)

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934
2. Guallar E, Laine C. Controversy over clinical guidelines: Listen to the evidence, not the noise. Ann Intern Med 2014;160:361-2
3. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:484-93
4. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: A HuGE association review. Am J Epidemiol 2004;160:421-9
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
6. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 1986;256:2823-8
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation 2002;106:3143-421
8. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6
9. Steinberg D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy. J Lipid Res 2006;47:1339-51
10. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44
11. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
13. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
14. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
15. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
16. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
17. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
18. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
19. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-64
20. Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45
21. Talwalkar PG, Sreenivas CG, Gulati A, Baxi H. Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. Indian J Endocrinol Metab 2013;17:628-35
22. Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel II). NIH Publication No. 93-3095, September, 1993. Available from: http://www.fda.gov/ohrms/dockets/ dockets/01q0313/01q-0313-hcn0001-60-reference-46-vol3.pdf. [Last accessed on 2015 Jun 11]
23. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39
24. Avai lab le from: ht t p://www. iom.edu/Repor ts/2011/ Clinical-Practice-Guidelines-We-Can-Trust.aspx. [Last acccessed on 2015 Jun 11]
25. Grundy SM. Then and Now: ATP III vs. IV Lipid Lowering Paradigm Shifts with Newer Guidelines. CardioSource World New; 2014. p. 36-7. Available from: http://www.joomag.com/magazine. [Last accessed on 2015 Jun 11]
26. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International atherosclerosis society position paper: Global recommendations for the management of dyslipidemia-full report. J Clin Lipidol 2014;8:29-60
27. Ridker PM, Cook NR. Statins: New American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1762-5
28. Pencina MJ, Navar-Boggan AM, D'Agostino RB, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422-31
29. Zhuo X. Implications of New American Heart Association (AHA)/ American College of Cardiology (ACC) Cholesterol Guidelines on Diabetes Care and Prevention: Balancing the Benefits and Costs. Oral Paper Presentation at ADA, (Number 17-OR. Category Health Care Delivery/Economics); 2014. Available from: http://www. medscape.com/viewarticle/826775. [Last accessed on 2015 Jun 11]
30. Mohan S, Reddy KS, Prabhakaran D. Chronic non-communicable diseases in India. Reversing the tide. Public Health Found India; 2011. Available from: http://www.phfi.org/images/what-we-do/ PHFI-NCD-Report-Sep-2011.pdf. [Last accessed on 2015 Jun 11]
31. McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in South Asians overseas: A review. J Clin Epidemiol 1989;42:597-609
32. Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J 1996;48:343-53
33. Pais P, Pogue J, Gerstein H, Zachariah E, Savitha D, Jayprakash S, et al. Risk factors for acute myocardial infarction in Indians: A case-control study. Lancet 1996;348:358-63
34. Kulkarni KR, Markovitz JH, Nanda NC, Segrest JP. Increased prevalence of smaller and denser LDL particles in Asian Indians. Arterioscler Thromb Vasc Biol 1999;19:2749-55
35. Bhatnagar D, Anand IS, Durrington PN, Patel DJ, Wander GS, Mackness MI, et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995;345:405-9
36. Deedwania P, Singh V. Coronary artery disease in South Asians: Evolving strategies for treatment and prevention. Indian Heart J 2005;57:617-31
37. Hoogeveen RC, Gambhir JK, Gambhir DS, Kimball KT, Ghazzaly K, Gaubatz JW, et al. Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res 2001;42:631-8
38. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: What clinicians should know. Circulation 2006;113:e924-9
39. Khanna R, Kapoor A, Kumar S, Tewari S, Garg N, Goel PK. Metabolic syndrome and Framingham risk score: Observations from a coronary angiographic study in Indian patients. Indian J Med Res 2013;137:295-301
40. Kanjilal S, Rao VS, Mukherjee M, Natesha BK, Renuka KS, Sibi K, et al. Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. Vasc Health Risk Manag 2008;4:199-211
41. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41
42. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 2007;99:1538-43
43. Kaul U, Varma J, Kahali D, Hiremath MS, Dani S, Dalal J, et al. Post-marketing study of clinical experience of atorvastatin 80 mg vs. 40 mg in Indian patients with acute coronary syndrome-A randomized, multi-centre study (CURE-ACS). J Assoc Physicians India 2013;61:97-101
44. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A go-DARTS study. Clin Pharmacol Ther 2011;89:210-6
45. Mahadevan L, Yesudas A, Sajesh PK, Revu S, Kumar P, Santhosh D, et al. Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala. Indian J Hum Genet 2014;20:175-84
46. Choudhry NK, Dugani S, Shrank WH, Polinski JM, Stark CE, Gupta R, et al. Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. Health Aff (Millwood) 2014;33:273-82
47. Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Clin Pharmacol 2014;3:954-7
48. Aggarwal A. Saroglitazar: India's answer to diabetic dyslipidemia. Int J Pharmacol Clin Sci 2014;3:7-14
49. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82
50. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): A pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol 2015;3:339-55